Reported Earlier, Novo Nordisk Wins FDA Approval For Awiqli As First-Ever Once-Weekly Basal Insulin Cutting Injections From Seven To One Per Week

Novo Nordisk has received FDA approval for Awiqli (insulin icodec-abae), marking it as the first-ever once-weekly basal insulin. This new treatment option allows adults with type 2 diabetes to reduce their insulin injections from seven per week to just one. The approval underscores the company's commitment to healthcare innovation and support for diabetes management.